Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members

被引:82
作者
Lomax, ME
Barnes, DM
Hupp, TR
Picksley, SM
Camplejohn, RS
机构
[1] United Med & Dent Sch Guys & St Thomas Hosp, Richard Dimbleby Dept Canc Res, London SE1 7EH, England
[2] Guys Hosp, Clin Oncol Unit, ICRF, London SE1 9RT, England
[3] Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland
[4] Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England
关键词
p53; Li-Fraumeni syndrome; oligomerization domain; MDM2; apoptosis; transactivation;
D O I
10.1038/sj.onc.1201974
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
p53 is a tumour suppressor gene which functions as a transcription factor to upregulate genes for growth arrest and apoptosis following DNA damage. p53 mutations are associated with Li-Fraumeni and Li-Fraumeni like syndromes. Recently mutations of the oligomerization domain have been isolated from an LFS and an LFL family affecting respectively codon 344 (Leu to Pro) and 337 (Arg to Cys). The present study was designed to determine the affect of these mutations on the function of pJ3 protein, p53 344 Leu to Pro existed only in a monomeric form and could not bind to DIVA. It was inactive at inducing apoptosis, transactivating luciferase from a bax promoter and inhibiting cell growth. In contrast, p53 337 Arg to (Cys could form tetramers and could bind to DNA. However, p53 337 Arg to Cys was not fully active and could only induce apoptosis, transactivate luciferase from a bax promoter and inhibit cell growth with approximate to 60% of the ability of wild-type p53. Both mutant proteins had reduced ability to bind to MDM2, p53 337 Arg to Cys being more reduced than p53 344 Leu to Pro. These results indicate that point mutations in the oligomerization domain can disrupt p53 function. In addition, the value of LFS and LFL families for the further understanding of the biological and biochemical properties of p53 is demonstrated.
引用
收藏
页码:643 / 649
页数:7
相关论文
共 34 条
[1]   SUPPRESSION OF HUMAN COLORECTAL-CARCINOMA CELL-GROWTH BY WILD-TYPE-P53 [J].
BAKER, SJ ;
MARKOWITZ, S ;
FEARON, ER ;
WILLSON, JKV ;
VOGELSTEIN, B .
SCIENCE, 1990, 249 (4971) :912-915
[2]   MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY [J].
BARAK, Y ;
JUVEN, T ;
HAFFNER, R ;
OREN, M .
EMBO JOURNAL, 1993, 12 (02) :461-468
[3]   ABNORMAL EXPRESSION OF WILD TYPE-P53 PROTEIN IN NORMAL-CELLS OF A CANCER FAMILY PATIENT [J].
BARNES, DM ;
HANBY, AM ;
GILLETT, CE ;
MOHAMMED, S ;
HODGSON, S ;
BOBROW, LG ;
LEIGH, IM ;
PURKIS, T ;
MACGEOCH, C ;
SPURR, NK ;
BARTEK, J ;
VOJTESEK, B ;
PICKSLEY, SM ;
LANE, DP .
LANCET, 1992, 340 (8814) :259-263
[4]   LI-FRAUMENI SYNDROME [J].
BIRCH, JM .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (13) :1935-1941
[5]  
Casey G, 1996, ONCOGENE, V13, P1971
[6]  
DAVISON T, UNPUB ONCOGENE SIMUL
[7]   DEFINITION OF A CONSENSUS BINDING-SITE FOR P53 [J].
ELDEIRY, WS ;
KERN, SE ;
PIETENPOL, JA ;
KINZLER, KW ;
VOGELSTEIN, B .
NATURE GENETICS, 1992, 1 (01) :45-49
[8]   A SIMPLE P53 FUNCTIONAL ASSAY FOR SCREENING CELL-LINES, BLOOD, AND TUMORS [J].
FLAMAN, JM ;
FREBOURG, T ;
MOREAU, V ;
CHARBONNIER, F ;
MARTIN, C ;
CHAPPUIS, P ;
SAPPINO, AP ;
LIMACHER, JM ;
BRON, L ;
BENHATTAR, J ;
TADA, M ;
VAN MEIR, EG ;
ESTREICHER, A ;
IGGO, RD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (09) :3963-3967
[9]   Database of p53 gene somatic mutations in human tumors and cell lines: Updated compilation and future prospects [J].
Hainaut, P ;
Soussi, T ;
Shomer, B ;
Hollstein, M ;
Greenblatt, M ;
Hovig, E ;
Harris, CC ;
Montesano, R .
NUCLEIC ACIDS RESEARCH, 1997, 25 (01) :151-157
[10]   Mdm2 promotes the rapid degradation of p53 [J].
Haupt, Y ;
Maya, R ;
Kazaz, A ;
Oren, M .
NATURE, 1997, 387 (6630) :296-299